ClinicalTrials.gg
RecruitingNCT07937553ChromoKeyUpdated Nov 16, 2026

Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma: a Phase 2 Study.

A Phase 2 interventional study of Lenvatinib and Pembolizumab in Metastatic Chromophobe Renal Cell Carcinoma, sponsored by Kidney Cancer Research Bureau. Recruiting at 8 sites in Russia. Open to participants aged 18 Months and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Kidney Cancer Research Bureau · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Aug 2025, registered Nov 2026).
  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 48 studies testing everolimus in Carcinoma, Renal Cell — 4 open to participants now, 7 under way, 2 of them phase 3. Everolimus · Carcinoma, Renal Cell.

Planned enrollment
27th of 48
40 · median 46
Started
2025
with 1 other
Phase 2
26 of 48
2 open now
Registered
48th of 48
by date
Lead sponsor
2 of 48
Kidney Cancer Research Bureau

Among the 48 studies testing everolimus in Carcinoma, Renal Cell, this one is the 27th largest by planned enrollment, is one of 2 that started in 2025, is one of 26 in phase 2, and was the 48th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

4 of the 48 studies testing everolimus in Carcinoma, Renal Cell are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About everolimus

Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: 18 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing everolimus in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

Chromophobe renal cell carcinoma (chRCC) accounts for approximately 5% of RCC cases and has distinct morphological and molecular features. However, advanced chRCC follows an aggressive clinical course and responds poorly to standard regimens developed for clear cell RCC.

Lenvatinib plus everolimus (LEN+EVE) has demonstrated clinical activity in clear cell RCC (Study 205), with responses also reported in non-clear cell subtypes, including chRCC. Lenvatinib plus pembrolizumab (LEN+PEMBRO) demonstrated a high objective response rate (ORR) in KEYNOTE-B61, including in the chRCC subgroup.

These findings support conducting a prospective phase 2 study specifically dedicated to this rare subtype to provide direct evidence of the efficacy and safety of these two active combinations.

Read the detailed description

ChromoKey is a prospective, open-label, multicenter, two-cohort, non-randomized phase 2 study evaluating the efficacy and safety of first-line lenvatinib plus pembrolizumab (Cohort A) and later-line lenvatinib plus everolimus (Cohort B) in patients with metastatic chromophobe renal cell carcinoma (chRCC).

The study enrolls 40 patients across two independent cohorts, with 20 patients in each cohort. Eligible patients are adults with histologically confirmed metastatic chRCC, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3, and measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Patients from all International Metastatic RCC Database Consortium (IMDC) risk groups are eligible.

Cohort A includes patients who have received no previous systemic therapy for metastatic disease. Patients receive lenvatinib 20 mg orally once daily in combination with pembrolizumab 200 mg intravenously every 3 weeks.

Cohort B includes patients whose disease progresses following previous systemic therapy and who have not previously received lenvatinib. Patients receive lenvatinib 18 mg orally once daily in combination with everolimus 5 mg orally once daily. Treatment continues until disease progression or unacceptable toxicity.

The primary endpoint is the objective response rate in each cohort, defined as the proportion of patients achieving a complete or partial response according to RECIST version 1.1.

Secondary endpoints include progression-free survival, overall survival, duration of response, and safety. Tumor response is evaluated using radiological assessments, and safety is assessed through monitoring of adverse events, clinical examinations, and laboratory investigations.

Each cohort is evaluated independently to characterize the activity and tolerability of the respective combination in its treatment setting. The study does not include randomization or a formal comparison between the two cohorts.

03

Conditions studied

  • Metastatic Chromophobe Renal Cell Carcinoma

Keywords

  • lenvatinib
  • pembrolizumab
  • everolimus
04

Who can participate

Ages eligible
18 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed chromophobe renal cell carcinoma.
  • according to version 1.1.
  • performance status of 0-3.
  • Cohort A: No prior systemic therapy for disease.
  • Cohort B: Disease progression following prior systemic therapy and no previous exposure to lenvatinib
  • Adequate bone marrow, hepatic, and renal function.
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled or symptomatic central nervous system or .
  • Uncontrolled hypertension despite appropriate antihypertensive treatment.
  • uncontrolled cardiovascular disease.
  • Active infection requiring systemic treatment.
  • Active clinically significant bleeding or a high risk of severe hemorrhage.
  • Major surgery without adequate postoperative recovery or a serious non-healing wound.
  • Gastrointestinal conditions that significantly impair the absorption of oral study medications.
  • Known severe to any component of the assigned study treatment.
  • Current pneumonitis or interstitial lung disease.
  • Pregnancy or breastfeeding.
  • Any medical or psychiatric condition that, in the investigator's judgment, compromises patient safety or adherence to study procedures.
  • Cohort A only: Active disease requiring systemic treatment, or a requirement for chronic systemic immunosuppression, excluding physiological replacement.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Cohort A: first-line lenvatinib plus pembrolizumab

    lenvatinib 20 mg orally once daily in combination with pembrolizumab 200 mg intravenously every 3 weeks

    Drug: Lenvatinib · Drug: Pembolizumab

  • Experimental
    Cohort B: later-line lenvatinib plus everolimus

    lenvatinib 18 mg orally once daily in combination with everolimus 5 mg orally once daily

    Drug: Lenvatinib · Drug: everolimus

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate

    the proportion of patients achieving a complete or partial response according to RECIST version 1.1

    Time frame: 12 months

Secondary outcomes

  1. progression-free survival

    the time from treatment initiation to the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first.

    Time frame: 24 months

  2. overall survival

    the time from treatment initiation to death from any cause

    Time frame: 24 months

  3. duration of response

    the time from the first documented complete or partial response to disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first

    Time frame: 24 months

  4. Grade 3 and higher treatment-emergent adverse events

    the proportion of patients experiencing at least one treatment-emergent adverse event of grade 3 or higher according to NCI CTCAE version 5.0.

    Time frame: 24 months

07

Study locations

8 of 8 sites recruiting
  • Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
    Chelyabinsk, Russia
    Recruiting
  • V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University
    Krasnoyarsk, Russia
    Recruiting
  • Orenburg Regional Cancer Center
    Orenburg, Russia
    Recruiting
  • Dr. Berezin Medical Institute
    Saint Petersburg, Russia
    Recruiting
  • SBHI Leningrad regional clinical hospital, Saint-Petersburg
    Saint Petersburg, Russia
    Recruiting
  • Saratov Regional Cancer Center
    Saratov, Russia
    Recruiting
  • Republican Clinical Oncology Dispensary
    Ufa, Russia
    Recruiting
  • Sverdlovskiy Regional Oncological Dispensary
    Yekaterinburg, Russia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Study results are disseminated through scientific publications and conference presentations in aggregate form.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Aug 2027, 23 months after the start.

Of 183 non-industry phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 98. This study's planned 23 months is below that.

Counting every sponsor, half of 230 studies reached it within 58 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartActual
Aug 15, 2025
Primary completionEst.
Aug 1, 2027
CompletionEst.
Dec 30, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937553
Lead sponsor
Kidney Cancer Research Bureau
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Aug 15, 2025
Primary completion
Aug 1, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Ilya Tsimafeyeu
Contact
bucare@bucare.org
+74999054690

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion